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Eight- to Ten-Year Follow-up in Early Cases 
of Renal Homotransplantation 
By C. G. Halgrimson, I. Penn, A. Booth, C. Groth, C. W. Putnam, J. Corman, and T. E. Starzl 
l 1H1S report will be concerned with a 
medicat social, and psychiatric follow-
up on a group of patients treated by renal 
homotransplantation from 81/2 to 10 yr ago 
at the Denver Veterans Administration and 
Colorado General Hospitals. 
CASE MATERIAL 
The 64 patients who underwent trans-
plantation between November, 1962 and 
March, 1964 have been extensively de-
scribed in journals and in a book based 
almost entirely on these cases.1.2 There 
were 46 recipients of consanguineous kid-
neys from 23 siblings, 20 parents, one aunt, 
one uncle, and one cousin, and 18 recip-
ients of nonrelated kidneys donated by 
healthy volunteers. Immunosuppression 
was with azathioprine and prednisone, 
using two regimens. In 45 cases azathio-
prine was started alone; prednisone was 
added in 43 of these 45 patients with the 
appearance of clinically obvious rejection. 
In the other 19 recipients both drugs were 
administered from the outset. 
Typing procedures were not available 
when this series was compiled. Conse-
quently, the donor-recipient matching was 
not by any kind of immunologic guidelines 
except for the avoidance in all cases after 
case 23 of the kind of red blood cell type 
incompatibility that can lead to hyperacute 
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rejection. l Parenthetically, one of our earli-
est recipients is still alive with perfect graft 
function 9 yr 8 mo after transplantation 
from a B+ type donor to A+ type recip-
ient, a combination which would no longer 
ever be used. 
All of the recipients had splenectomy. 
The first eight (of whom four are still 
living) had pretransplantation thymectomy. 
Nine additional patients had thymectomy 
81/2 to 17 mo after transplantation in the 
hope of being able to reduce immunosup-
pression. Five of the nine recipients are 
still alive but three of them have under-
gone retransplantation. Although thymec-
tomy may have a beneficial effect in 
humans2, it is no longer performed in our 
center. 
SURVIVAL 
The 46 Related Cases 
After a heavy mortality (33%) in the 
first 6 mo, subsequent deaths have been 
uncommon (Fig. 1). Of the 31 recipients 
who survived for a half year, 29 and 28 
lived for 3 and 5 yr, respectively, and 24 
are still alive after 81/2 to almost 10 yr. No 
one is now on dialysis and 21 of the 24 
have function of their original grafts; the 
other three had retransplantations 51/2,5%, 
and 7 yr after the first procedure and the 
secondary kidneys have subsequently func-
tioned for 41/3, 3%, and 11/2 yr. 
The outcome was not strikingly influ-
enced by the nature of the relationship 
whether this be parental, sibling, or other 
(Table 1). The parent-to-offspring results 
were amazingly stable in terms of recipient 
survival. At the end of 6 mo, 14 of 20 
recipients (70%) were alive. By 81/2-10 yr 
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Fig. 1. Life survival curves of 64 patients 
treated from November, 1962 to March, 
1964. The denominators in the related and 
non related curves refer to patient survival 
and the numerators to survival of the orig-
inal homograft. Thus, 22 of the 26 living 
recipients still bear primary grafts; the other 
four have had successful retransplants. 
there were still 13 (65%) alive, although 
three of these were by virtue of retrans-
plantation. Also of interest was the fact 
that all of the three distantly related renal 
grafts (aunt, uncle, and cousin) were pro-
viding superb function, nearly a decade 
after their insertion (Table 1). 
The causes of mortality in the first 5-yr 
follow-up of this series have been exhaus-
tively reportedL2 for which reason only 
the four deaths in the second 5 yr will be 
mentioned. Two patients with adequate 
renal function 81/4 and 9 yr posttransplan-
tation died of chronic aggressive hepatitis 
of several years' duration; one was Aus-
tralia-antigen positive. A third patient had 
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a fatal myocardial infarction after 71/3 yr. 
The fourth patient had a technically unsuc-
cessful retransplantation in the sixth year, 
and then committed suicide by refusing to 
be placed back on hemodialysis. 
The 18 Nonrelated Cases 
Two-thirds of the recipients died in the 
first year with a mortality that continued 
until only two patients were left at the 5-yr 
mark (Fig. 1). These two are still alive 
after 81/2 and 82/3 yr but in the second 
instance a second homograft from a mother 
has supported life for the last 6 yr of the 
total survival. 
GRAFT FUNCTION AND 
IMMUNOSUPPRESSION 
In Table 2 are shown the average cur-
rent renal functions of the 26 survivors, 
these values representing 22 primary kid-
neys that have functioned for 81/2 to nearly 
10 yr and four retransplants that have 
functioned for 11/2-41/3 yr. On the average, 
the older grafts are performing better than 
the more recent ones. The chronic immuno-
suppression being given those patients is 
also listed. The average daily doses of 
prednisone are small enough so that only 
one patient (the most recent retransplant) 
has a Cushing's facies. 
Arterial hypertension is an almost uni-
versal finding in the immediate posttrans-
plantation period and even for several years 
afterwards.1.2 This problem has tended to 
become less with longer follow-up. Only 
Table 1. The Influence of Consanguinity upon Present Survival in 46 Cases After 8-1 /2 to 9-5/6 Yr 
1 Yr 3 Yr 5 Yr Now 
Donor Patient Graft Patient Graft Patient Graft Patient Graft 
20 Parents 14 14 14 14 14 (70%) 14 (70%) 13 (65%)* 10 (50%) 
23 Siblings 14 14 12 12 11 (48%) 11 (48%) 8 (35%) 8 (35%) 
3 Aunt, uncle. 
or cousin 3 3 3 3 3 (100%) 3 (100%) 3 (100%) 3 (100%) 
*Retransplantation was carried out after 5'12, 53/4, and 7 yr. 
RENAL HOMOTRANSPLANTATION 
one of the survivors (and this the retrans-
plant of 11/2 yr ago) has severe hyperten-
sion. Five other patients receive small daily 
doses of a combination of antihyperten-
sives. Fourteen recipients require no anti-
hypertensive therapy, and six are receiving 
only chlorothiazide. With the generally low 
steroid doses, there are no examples of 
steroid-induced diabetes. 
THE QUESTION OF CANCER 
Six of the 64 recipients (9%) including 
four who are still alive developed carcin-
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omas, the features of which are summarized 
in Table 3. All were skin cancers and treat-
ment was by standard surgical measures. 
50 far cancer has not been a cause of death 
in this original group of patients although 
we have had two deaths from de novo 
reticulum cell sarcomas in patients treated 
since 1964.2 
THE QUALITY OF LIFE 
The degree of rehabilitation in this group 
has been truly remarkable. All those who 
were adults at the time of transplantation 
Table 2. Average Current Renal Function and Immunosuppression in 26 Recipients of Renal 
Homografts Surviving 81/2-10 Yr Posttransplantation 
Serum Creatinine 
BUN Creatinine Clearance Azathioprine Prednisone 
Patient (mg 100 mil (mg 100 ml) (ml/min) (mg/day) (mg/day) 
LD 1- 22 1.6 90 125 15 
LD 2 16 1.7 70 100 0 
LD 3 11 1.1 130 150 0 
LD 6 20 1.3 105 200 10 
LD 12 18 1.4 70 100 15 
LD 13 19 1.4 90 87.5 7.5 
LD 14 10 0.9 120 200 0 
LD 17 9 0.8 70 100 2.5 
LD 22 17 0.8 90 137.5 10 
LD 25 22 1.6 80 50 10 
LD 33 12 1.2 90 125 0 
LD 34 31 1.5 60 50 0 
LD 37 11 1.0 94 150 15 
LD 39 17 1.0 80 125 10 
LD 41- 60 3.0 20 5 30 
LD 42 18 1.1 75 125 7.5 
LD 49 25 1.1 70 87.5 5 
LD 50- 49 2.0 45 75 20 
LD 51 21 1.3 85 125 10 
LD 52 17 0.8 110 150 5 
LD 53 25 1.6 55 100 5 
LD 54* + 25 1.1 85 125 15 
LD 55 27 1.4 40 150 20 
LD 58 16 1.4 65 137.5 10 
LD 60 46 3.3 40 87.5 20 
LD 63+ 27 1.4 80 125 15 
Mean ± SD 
22 Original grafts 19.8 ± 8.3 1.3 ± 0.5 80.4 ± 22.9 121.0 ± 38.8 8.1 ± 6.3 
Four retransplantation 39.0 ± 18.5 1.9 ± 0.8 60.0 ± 33.4 82.5 ± 56.8 20.0 ± 7.1 
All 36 patients 22.7 ± 12.2 1.4 ± 0.6 77.3 ± 25.2 115.1 ± 43.1 9.9 ±7.7 
'Patients surviving after retransplantation (LD 1, 4112 yr, LD 41,1 3/ 4 yr, LD 50, 3 yr, LD 54, 6 yr). 
tSurviving recipients of living unrelated renal homografts. 
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heave returned to some kind of full time 
work ranging from menial through tech-
nical to highly intellectual. 
Twelve of the survivors were younger 
than 18 yr (3-17) at the time of the original 
operation. They all returned to school, half 
graduated from college, eight now support 
themselves fully in adult work, and nine 
have married. The only one who has spent 
an excessive amount of time in the hospital 
is a child originally treated at the age of 3, 
whose original homograft failed, and who 
subsequently required retransplantation. He 
is now 12 years old and is stunted in 
growth. His prognosis to reach emotional 
and physical maturity is doubtful. 
At the time of this original series, poten-
tial recipients were screened with great care 
to rule out those with possible important 
psychiatric problems. Because of this, it 
has not been surprising to find exceptional 
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emotional stability among those who were 
accepted and who are still surviving. Excel-
lent adjustments have been made in spite 
of such serious early postoperative compli-
cations as aseptic necrosis of one or both 
of the femoral heads in three of the adoles-
cents. These latter patients have learned to 
walk adequately in spite of their handicaps. 
Many of the young patients were stunted 
in growth before and after transplantations 
and have had catch-up growth spurts late 
in their teens. 
Nine of the 64 patients of the original 
series have had children of their own, in-
cluding three by two female and 10 by 
seven male recipients. One of these off-
spring had a meningomyelocele which re-
quired surgical correction. It is of interest 
that all the children issuing from this trans-
plant population came from those 26 still 
surviving. Thus, no orphans have so far 
Table 3. Features of Cancers in Original Colorado Transplant ReCipients 
Time of 
Onset Follow-up 
After After Initial 
Trans- Diagnosis of 
Patient plant Tumor 
Number (Mo) Type of Tumor Treatment Outcome (Mo) 
LD 63 66 Squamous cell Wide excision No recurrence 35 
carcinoma lower 
lip 
LD 30 32 Squamous cell Wide excision No recurrence; 20 
carcinoma skin died of perforated 
of ear dive rticu litis 
LD 6 75 Basal cell carcinoma Wide excision No recurrence 38 
nasolabial fold 
LD 48 74 Squamous cell Multiple Died of myocardial 14 
carcinomas excisions infarction 
forearms, right 
arm, and scalp 
LD 60 78 Squamous cell Excisions and No recurrence 24 
carcinomas-two skin graft of 
of left hand and hand 
one of face 
LD 55 87 Squamous cell Wide excision Eight months later 15 
carcinoma face and skin graft had radical neck 
dissection for 
lymph node 
metastases 
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been created by the premature death of a 
transplant patient. 
DISCUSSION 
It is axiomatic that some degree of immu-
nologic weakening must be accepted as the 
price of success after whole organ trans-
plantation under immunosuppression. Be-
cause of this, it was once feared that a real 
margin of safety might not exist which 
would permit effective graft protection 
without killing the host. The fallacy of this 
assumption as it applies to the early post-
operative course has long since been 
proved. Now, there is evidence that immu-
nosuppression may be tolerated for inter-
vals that will extend beyond a decade in 
many instances. 
In the early days of transplantation, the 
feared specter with chronic immunosup-
pressive therapy was infection particularly 
with opportunistic organisms for which ef-
fective treatment is not available. A second 
concern has more recently derived from the 
well-documented increased incidence of de 
novo cancer in the transplant population. 
Both anxieties have a real basis as the ob-
servations in this early series have shown. 
Yet, the incidence and severity of late infec-
tion or tumors has by no means cancelled 
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the effectiveness of treatment by trans-
plantation. 
Instead, with each passing year the case 
is strengthened that transplantation repre-
sents one of the greatest, although as yet 
incompletely exploited, therapeutic achieve-
ments of modern medicine. It has become 
clear that about half of the original series 
of related kidney recipients are going to 
move into the second decade of their con-
valescence. The poorer results in non-
related transplantation would have been 
discouraging if it were not for the great 
progress made in many centers including 
our own with cadaver transplantation since 
the spring of 1964, when the presently re-
ported series was completed. 
SUMMARY 
Sixty-four consecutive patients under-
went renal homotransplantation 81/2 to al-
most 10 yr ago, 46 from related and 18 
from nonrelated living donors. Twenty-
four (52 %) of the 46 consanguineous recip-
ients survive to date, in 21 cases with func-
tion of the original grafts. Only two of the 
18 recipients of nonrelated kidneys survive 
and one of these patients has undergone 
retransplantation. The patients who are 
alive have had a high and continuing de-
gree of rehabilitation. 
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